Senior Medical Affairs & Market Access Consultant

Evaluated WNT/CDx implications for Roche's breast cancer CDx portfolio and associated therapies through KOL interviews, questionnaires, market research and advisory boards. Mapped clinical use of HRD testing across ovarian, prostate and breast cancer via desk research and expert interviews. Designed and delivered a comprehensive HRD training program covering biology, guideline status and clinical applications for internal teams

Led the launch of 2 innovative therapies for Pompe and ASMD, ensuring early access ahead of reimbursement, leading a team of 2 medical advisors. Developed and implemented compassionate use and patient support programs. Advised Market Access on reimbursement strategy and authored scientific sections of reimbursement, unmet need and Galenus dossiers. Built strong relationships with scientific societies, health authorities, and KOLs to drive endorsement and advocacy for these innovative therapies. Coordinated investigator-initiated research projects, including a newborn screening pilot

Drove market access for Praluent, Dupixent and Aubagio, covering pathology, unmet need, clinical evidence and pharma-economics. Authored reimbursement dossiers and negotiated with health authorities, including Managed Entry Agreements (MEA). Built strong relationships with KOLs, payers and trade associations to support reimbursement processes. Provided scientific and clinical input to cross-functional teams to align strategy and evidence needs

Led medical affairs for Praluent, including launch, early patient access and several disease awareness initiatives. Implemented an early access program for severe hypercholesterolemia patients prior to reimbursement. Drove FH diagnosis improvement through lab engagement, consensus development (BEL-FaHST), and targeted medical projects. Advised Market Access on the scientific components of the Praluent reimbursement dossier. Managed a team of two MSLs and coordinated cross-functional medical activities

Led medical affairs activities to prepare the market for the launch of Edoxaban, including KOL engagement, advisory boards and scientific communication. Developed and executed pre-launch strategies, including dissemination of Phase III clinical trial results through speaker bureaus and targeted publication initiatives. Delivered medical and scientific training on disease, pharmacology and trial data for MSLs and KAMs. Coordinated cross-functional medical activities and ensured alignment with commercial and market access teams, leading a team of 4 MSLs

Held progressive roles across education, product management, sales, marketing and business development in cardiac rhythm management, vascular intervention and cardiac surgery, culminating in leadership positions as Marketing Manager Belgium and Marketing & Business Development Manager for the EMEA Distributor Region

Conducted molecular immunology research at Vrije Universiteit Brussel